LMN.V vs. VRNA

Last updated Jun 9, 2026

LMN.V (Lumine Group Inc) and VRNA (Verona Pharma plc) are both stocks. LMN.V operates in Software - Application (Technology), while VRNA operates in Biotechnology (Healthcare). At a 0.02 correlation, their price movements are largely independent.

Performance

LMN.V vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in Lumine Group Inc (LMN.V) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

LMN.V is traded in CAD, while VRNA is traded in USD. To make them comparable, the VRNA values have been converted to CAD using the latest available exchange rates.

Returns By Period

LMN.V

• 1D: -3.21%
• 1M: 11.96%
• YTD: -16.54%
• 6M: -20.50%
• 1Y: -50.93%
• 3Y*: 5.50%
• 5Y*: —
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

LMN.V vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
LMN.V Lumine Group Inc	-16.54%	-34.03%	37.59%	84.00%
VRNA Verona Pharma plc	0.00%	123.73%	153.38%	-3.41%

Correlation

The correlation between LMN.V and VRNA is -0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.01
Correlation (3Y) Calculated over the trailing 3-year period	0.01
Correlation (All Time) Calculated using the full available price history since Mar 24, 2023	0.02

Fundamentals

Market Cap LMN.V : CA$5.81B VRNA : $9.72B
EPS LMN.V : CA$0.48 VRNA : -$0.69
PS Ratio LMN.V : 7.03 VRNA : 57.97
PB Ratio LMN.V : 7.00 VRNA : 34.92
Total Revenue (TTM) LMN.V : CA$792.89M VRNA : $167.65M
Gross Profit (TTM) LMN.V : CA$271.95M VRNA : $159.52M
EBITDA (TTM) LMN.V : CA$253.96M VRNA : -$40.86M

Return for Risk

LMN.V vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LMN.V

LMN.V Risk / Return Rank: 10
LMN.V Sharpe Ratio Rank: 6
LMN.V Sortino Ratio Rank: 5
LMN.V Omega Ratio Rank: 7
LMN.V Calmar Ratio Rank: 13
LMN.V Martin Ratio Rank: 18

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LMN.V vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lumine Group Inc (LMN.V) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LMN.V	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.96	—	—
Sortino ratio: Return per unit of downside risk	-1.65	—	—
Omega ratio: Gain probability vs. loss probability	0.82	—	—
Calmar ratio: Return relative to maximum drawdown	-0.77	—	—
Martin ratio: Return relative to average drawdown	-1.13	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	LMN.V	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.96	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	—	—

Drawdowns

Drawdown Indicators

	LMN.V	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-66.64%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-66.64%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-66.64%	—	—
Current Drawdown Current decline from peak	-58.26%	—	—
Average Drawdown Average peak-to-trough decline	-17.68%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	45.06%	—	—

Volatility

Volatility by Period

	LMN.V	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.32%	—	—
Volatility (6M) Calculated over the trailing 6-month period	38.82%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	53.25%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.05%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	45.05%	—	—

Dividends

LMN.V vs. VRNA - Dividend Comparison

Neither LMN.V nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

LMN.V vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Lumine Group Inc and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LMN.V - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a gross profit of 43.76M and revenue of 204.93M. Therefore, the gross margin over that period was 21.4%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

LMN.V - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported an operating income of 28.74M and revenue of 204.93M, resulting in an operating margin of 14.0%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

LMN.V - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a net income of 18.70M and revenue of 204.93M, resulting in a net margin of 9.1%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both LMN.V and VRNA in my portfolio?

LMN.V and VRNA have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.